{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:39:33Z","timestamp":1790746773995,"version":"4.1.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The sonidegib and ruxolitinib combination was assessed in an open-label study in JAK inhibitor-naive patients with myelofibrosis (MF). The primary objective of phase 1b was to establish the maximum tolerated dose (MTD) and\/or recommended phase 2 dose (RP2D) and phase 2 was to assess spleen volume reduction at weeks 24 and 48. Fifty patients were enrolled. In the dose-escalation phase (n = 23), doses for sonidegib once daily\/ruxolitinib twice daily were 400\/10 mg (level 1, n = 8), 400\/15 mg (level 2, n = 10), and 400\/20 mg (level 3, n = 5). Two patients had dose-limiting toxicity at level 2: increased blood creatine phosphokinase (grades 3 and 4, n = 1 each). MTD\/RP2D was determined as sonidegib 400 mg daily + ruxolitinib 20 mg twice daily. In phase 1b expansion and phase 2 stage 1 (n = 27), by weeks 24 and 48, \u226535% reduction in spleen volume was observed in 44.4% and 29.6% patients, respectively. By weeks 24 and 48, 42.0% and 26.0% patients had \u226550% reduction in Myelofibrosis Symptom Assessment Form total symptom score, respectively. Most common treatment-related adverse events (grade 3\/4) were increased blood creatine phosphokinase (18%), anemia (14%), and thrombocytopenia (12%). Four deaths were reported due to multiple organ dysfunction syndrome (on-treatment; no relationship with study treatment), acute myeloid leukemia, MF progression, and aspiration pneumonia. Although well tolerated, this combination will not be further developed in MF patients due to modest overall benefit compared with historical ruxolitinib monotherapy. This trial was registered at www.clinicaltrials.gov as #NCT01787552.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001212","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T16:03:04Z","timestamp":1594137784000},"page":"3063-3071","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b\/2 dose-finding study"],"prefix":"10.1182","volume":"4","author":[{"given":"Vikas","family":"Gupta","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Wolleschak","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, University Medical Center Magdeburg, Magdeburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3936-8032","authenticated-orcid":false,"given":"Hans","family":"Hasselbalch","sequence":"first","affiliation":[{"name":"Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro Maria","family":"Vannucchi","sequence":"first","affiliation":[{"name":"Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1011-8171","authenticated-orcid":false,"given":"Steffen","family":"Koschmieder","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Rheinisch-Westf\u00e4lische Technische Hochschule Aachen University, Aachen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Cervantes","sequence":"first","affiliation":[{"name":"Hospital Cl\u00ednic, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"first","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuochuan","family":"Dong","sequence":"first","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Wroclawska","sequence":"first","affiliation":[{"name":"Novartis AG, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savita","family":"Bharathy","sequence":"first","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Harrison","sequence":"first","affiliation":[{"name":"Guy\u2019s and St Thomas\u2019 National Health Service Foundation Trust, Guy\u2019s Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"issue":"9","key":"2020070711395258000_B1","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"2020070711395258000_B2","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-05-399048","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors","volume":"120","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"2020070711395258000_B3","first-page":"19803","volume-title":"Jakafi Prescribing Information","author":"US Food and Drug Administration","year":"2017"},{"issue":"9","key":"2020070711395258000_B4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"2020070711395258000_B5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1756-8722-7-18","article-title":"Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies","volume":"7","author":"Tibes","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"3","key":"2020070711395258000_B6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjh.13426","article-title":"Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?","volume":"170","author":"Khan","year":"2015","journal-title":"Br J Haematol"},{"issue":"2","key":"2020070711395258000_B7","first-page":"181","article-title":"Hedgehog beyond medulloblastoma and basal cell carcinoma","volume":"1805","author":"Teglund","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"2020070711395258000_B8","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nrc1229","article-title":"Hedgehog signalling in cancer formation and maintenance","volume":"3","author":"Pasca di Magliano","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2020070711395258000_B9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tips.2009.03.007","article-title":"Mechanisms of Hedgehog pathway activation in cancer and implications for therapy","volume":"30","author":"Scales","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"2020070711395258000_B10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.leukres.2019.02.012","article-title":"Phase 1\/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib [published correction appears in Leuk Res. 2019;81:105]","volume":"79","author":"Gerds","year":"2019","journal-title":"Leuk Res"},{"issue":"10","key":"2020070711395258000_B11","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1158\/1078-0432.CCR-17-2824","article-title":"Phase Ib study of glasdegib, a hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS","volume":"24","author":"Savona","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2020070711395258000_B12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"issue":"13","key":"2020070711395258000_B13","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40265-015-0458-y","article-title":"Sonidegib: first global approval","volume":"75","author":"Burness","year":"2015","journal-title":"Drugs"},{"issue":"21","key":"2020070711395258000_B14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.666.666","article-title":"Improved efficacy of combination of JAK2 and Hedgehog inhibitors in myelofibrosis [abstract]","volume":"122","author":"Bhagwat","year":"2013","journal-title":"Blood"},{"issue":"13","key":"2020070711395258000_B15","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2020070711395258000_B16","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The myelofibrosis symptom assessment form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk Res"},{"issue":"7","key":"2020070711395258000_B17","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1158\/1078-0432.CCR-13-1710","article-title":"A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors","volume":"20","author":"Rodon","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2020070711395258000_B18","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"2020070711395258000_B19","first-page":"35","article-title":"Role and inhibition of GLI1 protein in cancer","volume":"9","author":"Mastrangelo","year":"2018","journal-title":"Lung Cancer (Auckl)"},{"issue":"6","key":"2020070711395258000_B20","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","article-title":"Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial","volume":"16","author":"Migden","year":"2015","journal-title":"Lancet Oncol"},{"issue":"61","key":"2020070711395258000_B21","doi-asserted-by":"crossref","first-page":"104182","DOI":"10.18632\/oncotarget.22115","article-title":"Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy","volume":"8","author":"Ross","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"2020070711395258000_B22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-019-0236-2","article-title":"Myelofibrosis in 2019: moving beyond JAK2 inhibition","volume":"9","author":"Schieber","year":"2019","journal-title":"Blood Cancer J"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/13\/3063\/1748076\/advancesadv2019001212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/13\/3063\/1748076\/advancesadv2019001212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T16:03:31Z","timestamp":1594137811000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/13\/3063\/461266\/Safety-and-efficacy-of-the-combination-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":22,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001212","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]}}}